Patients with advanced solid tumors experienced significantly improved survival outcomes when receiving a tailored therapy based on the detection of the same genomic alteration in both tissue and liquid biopsies compared with both standard-of-care treatment and tailored therapy that was based on either biopsy on its own, according to results from the phase II, multicenter ROME trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, held April 25-30.